A U.S. federal judge has upheld the FDA’s decision to remove semaglutide, the active ingredient in Ozempic and Wegovy, from ...

Dr Scales explained that Parkinson's and Alzheimer's share commonality – both are neurodegenerative diseases with overlapping ...

Dietitians are especially excited about one underrated nutrient: prebiotic chicory root fiber. Let’s break down what GLP-1 is ...

After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson’s over a decade ago, experts from both fields will select the most promising drugs for both ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Fifty years of outstanding neuroscience research studies have revealed many secrets of how drugs of abuse affect and change ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...